[HTML][HTML] An EUA for Bamlanivimab-A monoclonal anti-body for COVID-19
M Orders - Med Lett Drugs Ther, 2020 - secure.medicalletter.org
M Orders
Med Lett Drugs Ther, 2020•secure.medicalletter.orgThe investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly)
has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently
diagnosed mild to moderate COVID-19 in patients who are≥ 12 years old, weigh at least 40
kg, and are at high risk for progressing to severe disease and/or hospitalization (see Table
1). 1Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical
outcomes when administered to hospitalized patients with COVID-19 requiring high flow …
has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently
diagnosed mild to moderate COVID-19 in patients who are≥ 12 years old, weigh at least 40
kg, and are at high risk for progressing to severe disease and/or hospitalization (see Table
1). 1Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical
outcomes when administered to hospitalized patients with COVID-19 requiring high flow …
The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are≥ 12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization (see Table 1). 1
Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. Bamlanivimab is not authorized for use in patients who are hospitalized or require oxygen therapy because of COVID-19.
secure.medicalletter.org
